Friday, 16 October 2026European Markets

PLAST.VAL LOIRE Stock 11.48% Up Today

Loading stream...

(vianews) - the market ended the session with plast.val loire (pvl.pa) rising 11.48% to €3.69 on monday while cac 40 rose 0.11% to €7,543.18.

plast.val loire's last close was €3.69, 0% below its 52-week high of €3.69.

about plast.val loire

plastiques du val de loire engages in the production and sale of plastic parts in france, north america, and internationally. the company offers interior equipment for vehicles, such as cockpits, decoration products, and mechanisms; exterior appearance parts; technical front facades; seat parts; lighting and signaling products; and under the hood parts. it also manufactures plastic products for use in construction and electricity, household electrical appliances, multimedia, leisure and garden, and luxury/design markets. the company was founded in 1963 and is headquartered in langeais, france.

earnings per share

as for profitability, plast.val loire has a trailing twelve months eps of €-1.47.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.52%.

revenue growth

year-on-year quarterly revenue growth grew by 13.3%, now sitting on 834.18m for the twelve trailing months.

volatility

plast.val loire's last week, last month's, and last quarter's current intraday variation average was 6.86%, 2.40%, and 2.04%.

plast.val loire's highest amplitude of average volatility was 6.86% (last week), 3.46% (last month), and 2.04% (last quarter).

volume

today's last reported volume for plast.val loire is 76219 which is 384.7% above its average volume of 15725.

more news about plast.val loire (pvl.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com